Intensity Therapeutics Inc

INTS

Company Profile

  • Business description

    Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

  • Contact

    1 Enterprise Drive
    Suite 430
    SheltonCT06484-4779
    USA

    T: +1 203 221-7381

    https://www.intensitytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    7

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,393.6924.780.30%
DAX 4026,742.537.42-0.03%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,947.3844.820.41%
HKSE23,753.84116.240.49%
NASDAQ25,136.27229.82-0.91%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,303.77130.090.92%
S&P 5007,561.670.000.00%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,602.5731.78-0.87%

Market Movers